Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Inmune Bio, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 34 | 36 | +2 |
| Shares | 2.30M | 2.02M | −282.5K (−12.3%) |
| Value | $19.3M | $17.7M | −$1.67M (−8.6%) |
New holders (5)
Institutions that held Inmune Bio, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 32,100 | $284.0K | 0.00% |
| Sepio Capital, LP | 22,000 | $194.0K | 0.02% |
| Northwestern Mutual Wealth Management Co | 4,300 | $38.0K | 0.00% |
| Citigroup Inc | 1,300 | $11.0K | 0.00% |
| The PNC Financial Services Group, Inc. | 820 | $8.00K | 0.00% |
Sold out (3)
Institutions that held Inmune Bio, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Marshall Wace, LLP | 67,373 | $568.0K |
| Susquehanna International Group, LLP | 52,042 | $438.0K |
| Alps Advisors Inc | 18,363 | $155.0K |